A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
Latest Information Update: 24 Jan 2024
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Cholangiocarcinoma
- Focus Adverse reactions
Most Recent Events
- 17 Jan 2024 Status changed from not yet recruiting to recruiting.
- 03 Aug 2023 New trial record